|
|
Article: Novocell Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes.
- Article from:
- Blood Weekly
- Article date:
- November 12, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Novocell, Inc., a preclinical stage diabetes company, announced that it will receive a Disease Team award totaling $20 million from the California Institute for Regenerative Medicine (CIRM). The Disease Team includes a group of scientists at the University of California, San Francisco (UCSF), led by Dr. Jeff Bluestone, which is contracted to receive $2.8 million. The funding will advance Novocell's development of a first in kind cellular therapy for the treatment of diabetes (see also Regenerative Medicine).
Novocell's proposal was selected for funding by CIRM's governing board, the Independent Citizens Oversight Committee (ICOC), with advisement from the ...